RecruitingNot ApplicableNCT07373236

The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes

Examining the Effect of Endogenous Glucagon-like Peptide-1 on Glucagon Secretion in Type 1 Diabetes

Sponsor

Asger Lund, MD

Enrollment

12 participants

Start Date

Jan 23, 2026

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes

Summary

Type 1 diabetes is a serious and burdensome disease that carries the risk of severe complications and premature death, partly due to low blood sugar, also called hypoglycaemia. This is a constant threat, as individuals with type 1 diabetes lack the body's natural safeguard against low blood sugar: the hormone glucagon, which is normally released from the pancreas. Recent research in mice suggests that this missing safeguard may be due to an imbalance in the hormones released from different cells in the pancreas. More specifically, glucagon-like peptide-1 (GLP-1) appears to play a role in the lack of glucagon secretion. By blocking this hormone using the substance exendin(9-39)NH₂, normalization of glucagon release during low blood sugar has been observed in mice with type 1 diabetes. The present study aims to investigate whether the same mechanism applies in humans with type 1 diabetes. If confirmed, this finding could form the basis for a novel adjunct treatment to insulin therapy and thereby potentially reduce the risk of hypoglycaemia in this patient group.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how a naturally produced gut hormone called GLP-1 affects the release of glucagon (a hormone that raises blood sugar) in people with type 1 diabetes, where the normal relationship between these hormones is often disrupted. **You may be eligible if...** - You are of Caucasian ethnicity - You are between 18 and 70 years old - You have had type 1 diabetes for 2 to 30 years, with an HbA1c below 8.5% - Your body mass index (BMI) is between 19 and 30 - You no longer produce insulin naturally (C-peptide negative) - You have been on a stable insulin regimen (pump or multiple daily injections) for at least 3 months **You may NOT be eligible if...** - You have anemia - You have late-stage complications of diabetes (except for mild eye disease) - You have liver or kidney disease - You are taking any blood sugar lowering medications other than insulin - You have had cancer in the last 5 years - You smoke or use nicotine products regularly Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.